Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01102218 · ClinicalTrials.gov registry record · Phase 2
A Safety Study of Pentoxifylline for the Treatment of Anemia
A Phase 2 study, sponsored by Fresenius Medical Care North America.
- Terminated
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT01102218 is a Phase 2 study that was terminated before completion, run by Fresenius Medical Care North America. The registered enrollment target is 48 participants.
The verdict
NCT01102218, a Phase 2 study, was terminated before completion, sponsored by Fresenius Medical Care North America.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
Chronic kidney disease (CKD) patients have increased levels of inflammation and oxidative stress, which in turn contribute to anemia and cardiovascular disease. Pentoxifylline is known to have anti-inflammatory and anti-oxidant properties, and has shown promise in improving the treatment of patients with anemia. This study will examine the use of pentoxifylline for the treatment of anemia in chronic kidney disease.
Interventions
- DRUG Pentoxifylline
- DRUG Erythropoietin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01102218
The ClinicalTrials.gov registry entry for NCT01102218 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fresenius Medical Care North America, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pentoxifylline is the first listed.
NCT01102218 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01102218 about?
NCT01102218 is a clinical study titled "A Safety Study of Pentoxifylline for the Treatment of Anemia". Chronic kidney disease (CKD) patients have increased levels of inflammation and oxidative stress, which in turn contribute to anemia and cardiovascular disease. Pentoxifylline is known to have anti-inflammatory and anti-oxidant properties, and has shown promise in improving the treatment of patient...
What is the current status of trial NCT01102218?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2010-08. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01102218?
The interventions under investigation include: Pentoxifylline (DRUG), Erythropoietin (DRUG).
Who is sponsoring clinical trial NCT01102218?
This trial is sponsored by Fresenius Medical Care North America, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.